Estrella nears completion of SPAC listing

Estrella Immunopharma nears completion of SPAC listing

The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
UPTD.US

Consumer

Discover hidden China stock gems in our weekly newsletter

Check out our content with some of our syndication partners

Ecommerce

Healthcare/biotech

This innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive.

RemeGen hopes for pain relief from expanded drug uses

The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: RemeGen’s…
9995.HK 688331.SHG
Estrella nears completion of SPAC listing

Estrella Immunopharma nears completion of SPAC listing

The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
UPTD.US
The drugs maker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings.

Debt pressures cast cloud over Fosun Pharma results

The drugmaker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings Key Takeaways:…
2196.HK 600196.SHG